CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Monte Rosa’s MRT-6160 Enters Phase 2 Trial in Psoriatic Arthritis

By Public Technologies
  • Novartis initiated a second Phase 2 study of Monte Rosa Therapeutics’ MRT-6160 (DDY391) in active moderate to severe psoriatic arthritis.
  • The first patient visit triggers a $37.5 million milestone payment under the partners’ exclusive global development and commercialization license agreement.
  • The randomized, placebo-controlled Phase 2a/b trial will evaluate efficacy, safety, tolerability and dose response.
  • A Phase 2 trial in Sjögren’s disease began in August; additional Phase 2 study initiations could trigger further milestone payments.
  • Phase 1 showed sustained, dose-dependent VAV1 degradation exceeding 90% in peripheral blood T cells, with no serious adverse effects observed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280700PRIMZONEFULLFEED9854312) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk